Nirsevimab

尼塞韦单抗

Report date: 2024/07/04 17:54:25

Base Information

Drug NameNirsevimab
Drug Alias NameRespiratory syncytial virus monoclonal antibody D25Beyfortus乐唯初SP-0232MEDI-8897 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionRespiratory syncytial virus F protein inhibitors
TargetsRespiratory syncytial virus F protein
Therapy Area/IndicationsLower Respiratory Tract InfectionsRespiratory Syncytial Virus Infections
Global Approved IndicationsLower Respiratory Tract InfectionsRespiratory Syncytial Virus Infections
Approved Indications in ChinaLower Respiratory Tract InfectionsRespiratory Syncytial Virus Infections
Original Approved Country/TerritoryEU
Original Approved Date2022/10/31
Country/TerritoryCzechiaBelgiumBulgaria +[35] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAimm TherapeuticsSanofiMedImmune Inc
China Registration ClassN/A

Develop Information

Active CompaniesSanofi PasteurSwedish Orphan Biovitrum Ab (Publ)Astrazeneca Plc +[8] 
Inactive CompaniesMedimmune LlcAstrazeneca Investment (China) Co Ltd
Active IndicationsLower Respiratory Tract InfectionsRespiratory Syncytial Virus Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A